Gary Nachman
Stock Analyst at BMO Capital
(3.29)
# 1,036
Out of 4,732 analysts
100
Total ratings
54.41%
Success rate
0.66%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $19.00 | +47.37% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $246.27 | +21.01% | 7 | Nov 1, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $37 | $22.50 | +64.44% | 1 | Sep 27, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $3.09 | +547.25% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $22.36 | +65.47% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $17.36 | +9.45% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $272.11 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $43.13 | -30.44% | 5 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $3.10 | +125.81% | 1 | Mar 28, 2024 | |
| VERU Veru Inc. | Initiates: Outperform | $3 | $0.98 | +207.57% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $189 | $171.56 | +10.17% | 13 | Feb 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $121.18 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $8.26 | -51.57% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $6.96 | +331.03% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $67 | $31.43 | +113.17% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $2.97 | +977.44% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $11.30 | +23.89% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $75 | $6.38 | +1,075.55% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $43 → $40 | $7.08 | +464.97% | 8 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $21.92 | -54.38% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $20.13 | +49.03% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.30 | +22,627.27% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $7.44 | +7.53% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $35.70 | -41.18% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $3.28 | +326.83% | 2 | Jun 14, 2018 |
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $19.00
Upside: +47.37%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $246.27
Upside: +21.01%
LENZ Therapeutics
Sep 27, 2024
Initiates: Outperform
Price Target: $37
Current: $22.50
Upside: +64.44%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $3.09
Upside: +547.25%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $22.36
Upside: +65.47%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $17.36
Upside: +9.45%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $272.11
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $43.13
Upside: -30.44%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $3.10
Upside: +125.81%
Veru Inc.
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.98
Upside: +207.57%
Feb 6, 2024
Maintains: Outperform
Price Target: $181 → $189
Current: $171.56
Upside: +10.17%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $121.18
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $8.26
Upside: -51.57%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $6.96
Upside: +331.03%
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $31.43
Upside: +113.17%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $2.97
Upside: +977.44%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $11.30
Upside: +23.89%
Nov 14, 2022
Maintains: Outperform
Price Target: $90 → $75
Current: $6.38
Upside: +1,075.55%
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $7.08
Upside: +464.97%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $21.92
Upside: -54.38%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $20.13
Upside: +49.03%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.30
Upside: +22,627.27%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $7.44
Upside: +7.53%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $35.70
Upside: -41.18%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $3.28
Upside: +326.83%